LGND - Ligand Pharmaceuticals Incorporated

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) 1.57
52-Week Change 3-41.49%
S&P500 52-Week Change 38.78%
52 Week High 3188.89
52 Week Low 384.45
50-Day Moving Average 398.93
200-Day Moving Average 3108.57

Share Statistics

Avg Vol (3 month) 3423.3k
Avg Vol (10 day) 3214.88k
Shares Outstanding 519.01M
Float 17.15M
% Held by Insiders 13.44%
% Held by Institutions 1130.68%
Shares Short (Sep 30, 2019) 47.32M
Short Ratio (Sep 30, 2019) 413.76
Short % of Float (Sep 30, 2019) 445.06%
Short % of Shares Outstanding (Sep 30, 2019) 438.48%
Shares Short (prior month Aug 30, 2019) 46.53M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4Jul 2, 2010
Last Split Factor (new per old) 26/1
Last Split Date 3Nov 19, 2010

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 389.58%
Operating Margin (ttm)38.06%

Management Effectiveness

Return on Assets (ttm)2.26%
Return on Equity (ttm)81.48%

Income Statement

Revenue (ttm)173.72M
Revenue Per Share (ttm)8.45
Quarterly Revenue Growth (yoy)-72.30%
Gross Profit (ttm)217.25M
Net Income Avi to Common (ttm)676.8M
Diluted EPS (ttm)30.55
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.39B
Total Cash Per Share (mrq)73.24
Total Debt (mrq)662.77M
Total Debt/Equity (mrq)63.64
Current Ratio (mrq)13.23
Book Value Per Share (mrq)53.71

Cash Flow Statement

Operating Cash Flow (ttm)43.85M
Levered Free Cash Flow (ttm)973.5M